168 related articles for article (PubMed ID: 35416342)
1. Review of venom immunotherapy at a regional tertiary paediatric centre.
Johnston N; Belcher J; Preece K; Bhatia R
J Paediatr Child Health; 2022 Jul; 58(7):1228-1232. PubMed ID: 35416342
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
3. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
5. Venom immunotherapy for preventing allergic reactions to insect stings.
Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
[TBL] [Abstract][Full Text] [Related]
6. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
7. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
8. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy.
Goldberg A; Confino-Cohen R
Ann Allergy Asthma Immunol; 2003 Oct; 91(4):405-10. PubMed ID: 14582821
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
10. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
[TBL] [Abstract][Full Text] [Related]
11. Rush Venom Immunotherapy in Children.
Confino-Cohen R; Rosman Y; Goldberg A
J Allergy Clin Immunol Pract; 2017; 5(3):799-803. PubMed ID: 27914814
[TBL] [Abstract][Full Text] [Related]
12. Modified rush venom immunotherapy in dogs with Hymenoptera hypersensitivity.
Moore A; Burrows AK; Rosenkrantz WS; Ghubash RM; Hosgood G
Vet Dermatol; 2023 Dec; 34(6):532-542. PubMed ID: 37395162
[TBL] [Abstract][Full Text] [Related]
13. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.
Hockenhull J; Elremeli M; Cherry MG; Mahon J; Lai M; Darroch J; Oyee J; Boland A; Dickson R; Dundar Y; Boyle R
Health Technol Assess; 2012; 16(12):III-IV, 1-110. PubMed ID: 22409877
[TBL] [Abstract][Full Text] [Related]
15. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
Sturm G; Kränke B; Rudolph C; Aberer W
J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
[TBL] [Abstract][Full Text] [Related]
16. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
17. Continuous immunotherapy for hymenoptera venom allergy using six month intervals.
Baenkler HW; Meusser-Storm S; Eger G
Allergol Immunopathol (Madr); 2005; 33(1):7-14. PubMed ID: 15777517
[TBL] [Abstract][Full Text] [Related]
18. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
19. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
20. Ultrarush immunotherapy in patients with Hymenoptera venom allergy.
Ruëff F; Przybilla B
J Allergy Clin Immunol; 2001 May; 107(5):928-9. PubMed ID: 11344369
[No Abstract] [Full Text] [Related]
[Next] [New Search]